Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis C

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 50 articles:
HTML format



Single Articles


    October 2023
  1. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    PubMed     Abstract available


  2. FELD JJ
    What is needed to move toward single-step diagnosis of current HCV infection?
    J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
    PubMed     Abstract available


  3. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  4. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
    Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
    J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
    PubMed     Abstract available


  5. CARTWRIGHT EJ, Patel PR
    Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
    J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
    PubMed     Abstract available


  6. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
    Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
    J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
    PubMed     Abstract available


  7. TERRAULT N
    Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
    J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
    PubMed     Abstract available


  8. PAGE K, Feinberg J
    What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
    J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
    PubMed     Abstract available


  9. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
    Lessons learned from global hepatitis C elimination programs.
    J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
    PubMed     Abstract available


  10. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  11. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  12. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  13. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  14. PRZYBYSZEWSKI EM, Chung RT
    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  15. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  16. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  17. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  18. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  19. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


    July 2023
  20. POWELL JG, Goble SR, Debes JD
    Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
    J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
    PubMed     Abstract available


  21. FIERER DS, Schinkel J
    Redefining the Paradigm: The Role of Sexual Networks and Sexualized Drug Use in the Transmission of HCV Among Men Who Have Sex with Men.
    J Infect Dis. 2023 Jul 24:jiad265. doi: 10.1093.
    PubMed    


    June 2023
  22. ARTENIE A, Stone J, Facente SN, Fraser H, et al
    Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
    J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  23. GAMKRELIDZE A, Shadaker S, Tsereteli M, Alkhazashvili M, et al
    Nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia, 2021.
    J Infect Dis. 2023 Mar 18:jiad064. doi: 10.1093.
    PubMed     Abstract available


    February 2023
  24. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
    Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
    J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
    PubMed     Abstract available


    October 2022
  25. MILLER-ARCHIE SA, Walters SC, Bocour A, Moore MS, et al
    The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


    August 2022
  26. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
    Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study.
    J Infect Dis. 2022;226:420-430.
    PubMed     Abstract available


  27. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
    Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    J Infect Dis. 2022;226:431-440.
    PubMed     Abstract available


  28. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication.
    J Infect Dis. 2022;226:407-419.
    PubMed     Abstract available


  29. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  30. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  31. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  32. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  33. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  34. CHUAYPEN N, Jinato T, Avihingsanon A, Chirapongsathorn S, et al
    Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection.
    J Infect Dis. 2021 Feb 17. pii: 6141513. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  35. KHERA T, Du Y, Todt D, Deterding K, et al
    Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C.
    J Infect Dis. 2021 Jan 31. pii: 6124746. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  36. JEYARAJAN AJ, Chung RT
    Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  37. BAJIS S, Applegate TL, Grebely J, Matthews GV, et al
    Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  38. CHAPPELL CA, Jonas MM
    Hepatitis C Virus in Pregnancy: Are We Ready for Test and Treat?
    J Infect Dis. 2020;222.
    PubMed    


  39. THOMAS DL
    30 Years on the Road to Hepatitis C Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  40. NAGGIE S, Wyles D
    Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    J Infect Dis. 2020;222.
    PubMed    


  41. FALADE-NWULIA O, Sulkowski MS
    Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  42. TROOSKIN SB, Dore G, Kostman J
    We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  43. ROCKSTROH JK, Boesecke C
    Hepatitis C Virus Treatment as Prevention: Challenges and Opportunities in Men Who Have Sex With Men.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  44. KAPPUS MR, Wolfe CR, Muir AJ
    Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  45. HALEY DF, Edmonds A, Ramirez C, French AL, et al
    Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV.
    J Infect Dis. 2020 Nov 3. pii: 5952700. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  46. VERGARA C, Valencia A, Thio CL, Goedert JJ, et al
    A multi-ancestry sex stratified genome-wide association study of spontaneous clearance of hepatitis C virus.
    J Infect Dis. 2020 Oct 29. pii: 5943036. doi: 10.1093.
    PubMed     Abstract available


  47. MESALAM AA
    Hepatitis C virus vaccine development: A step forward.
    J Infect Dis. 2020 Oct 11. pii: 5920711. doi: 10.1093.
    PubMed    


    September 2020
  48. SPRINGER SA, Barocas JA, Wurcel A, Nijhawan A, et al
    Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


  49. ROWAN SE, Kamis KF, Beum R, Bryan K, et al
    Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    J Infect Dis. 2020;222.
    PubMed     Abstract available


    August 2019
  50. KOSLOSKI MP, Oberoi R, Wang S, Viani RM, et al
    Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered with Human Immunodeficiency Virus Antiretrovirals.
    J Infect Dis. 2019 Aug 29. pii: 5556482. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.